How big is Bio-Techne Corp.?

As of Jun 18, Bio-Techne Corp. has a market capitalization of $7.76 billion, with net sales of $1.21 billion and a net profit of $131.65 million reported over the latest four quarters.

Market Cap: As of Jun 18, Bio-Techne Corp. has a market capitalization of 7,759.98 million, classifying it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Bio-Techne Corp. reported net sales of 1,208.77 million and a net profit of 131.65 million.<BR><BR>Balance Sheet Snapshot: As of Jun 24, the company reported shareholder's funds of 2,068.85 million and total assets of 2,813.19 million.

What does Bio-Techne Corp. do?

Bio-Techne Corporation develops and sells biotechnology reagents and instruments for research and clinical diagnostics, with recent net sales of $316 million and a market cap of approximately $7.76 billion. Key financial metrics include a P/E ratio of 37.00 and a dividend yield of 64.92%.

Overview: <BR>Bio-Techne Corporation develops, manufactures, and sells biotechnology reagents and instruments for the research and clinical diagnostic markets, operating in the Pharmaceuticals & Biotechnology industry within the mid-cap market segment.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 316 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 23 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 7,759.98 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 37.00 <BR>Dividend Yield: 64.92% <BR>Debt Equity: 0.10 <BR>Return on Equity: 10.25% <BR>Price to Book: 3.85<BR><BR>Contact Details: <BR>Address: 614 McKinley Pl NE, MINNEAPOLIS MN: 55413-2610 <BR>Tel: ['1 612 3798854', '1 646 2771266'] <BR>Fax: 1 612 6564400 <BR>Website: https://www.bio-techne.com/

Should I buy, sell or hold Bio-Techne Corp.?

Who are in the management team of Bio-Techne Corp.?

As of March 2022, the management team of Bio-Techne Corp. includes Independent Chairman Mr. Robert Baumgartner, President and CEO Mr. Charles Kummeth, and several Independent Directors: Ms. Julie Bushman, Mr. John Higgins, Dr. Joseph Keegan, Dr. Roeland Nusse, and Dr. Alpna Seth. This team provides governance and strategic direction for the company.

As of March 2022, the management team of Bio-Techne Corp. includes the following individuals:<BR><BR>- Mr. Robert Baumgartner, who serves as the Independent Chairman of the Board.<BR>- Mr. Charles Kummeth, who is the President, Chief Executive Officer, and a Director.<BR>- Ms. Julie Bushman, who is an Independent Director.<BR>- Mr. John Higgins, who is also an Independent Director.<BR>- Dr. Joseph Keegan, serving as an Independent Director.<BR>- Dr. Roeland Nusse, who is an Independent Director.<BR>- Dr. Alpna Seth, who is an Independent Director.<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Is Bio-Techne Corp. technically bullish or bearish?

As of October 3, 2025, Bio-Techne Corp. shows a neutral trend with mixed signals, including mildly bullish MACD and KST on weekly charts but bearish moving averages, while underperforming the S&P 500 with a year-to-date return of -14.04%.

As of 3 October 2025, the technical trend for Bio-Techne Corp. has changed from bearish to sideways. The current stance is neutral, with mixed signals across various indicators. The MACD shows a mildly bullish trend on both weekly and monthly time frames, while Bollinger Bands indicate a mildly bullish weekly stance but a mildly bearish monthly outlook. The moving averages are mildly bearish on a daily basis. The KST is bullish weekly but bearish monthly, and Dow Theory shows no trend weekly and mildly bullish monthly. <BR><BR>In terms of performance, Bio-Techne has underperformed the S&P 500 across multiple periods, with a year-to-date return of -14.04% compared to the S&P 500's 14.18%, and a one-year return of -17.20% versus 17.82% for the index.

Is Bio-Techne Corp. overvalued or undervalued?

As of October 17, 2025, Bio-Techne Corp. is considered very expensive and overvalued with a P/E ratio of 37, significantly higher than its peers, and has underperformed with a year-to-date return of -14.12% compared to the S&P 500's 13.30% gain.

As of 17 October 2025, the valuation grade for Bio-Techne Corp. has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company appears to be overvalued based on its current metrics, including a P/E ratio of 37, a Price to Book Value of 3.78, and an EV to EBITDA of 20.54. In comparison, peers such as Illumina, Inc. and BioMarin Pharmaceutical, Inc. have P/E ratios of 19.09 and 15.17, respectively, highlighting Bio-Techne's premium valuation relative to its industry.<BR><BR>The company's recent stock performance has been underwhelming, with a year-to-date return of -14.12%, contrasting sharply with the S&P 500's gain of 13.30% over the same period. Additionally, over the past three years, Bio-Techne's stock has declined by 79.11%, while the S&P 500 has increased by 81.19%, further reinforcing the notion that the stock is overvalued in its current state.